Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer’s disease

Table 1 Patients characteristics

Number of subjects (n)	17
Male / Female	10 (58.8%) / 7 (41.2%)
Early AD (MCI due to AD / mild dementia due to AD)	9 (52.9%) / 8 (47.1%)
	Mean ± SD (Min – Max)
Age at BL [years]	66.76 ± 6.34 (55–77)
Time to follow-up [months]	26.59 ± 2.21 (23–30)
CDR-global (BL)	0.70 ± 0.25 (0.5–1)
ΔCDR-global after 24 months	0.46 ± 0.51 (0.5–2)
CDR-SOB (BL)	4.09 ± 2.12 (0.50–9.00)
ΔCDR-SOB after 24 months	2.29 ± 2.74 (− 2.09–6.92)
MMSE (BL)	23.65 ± 3.39 (16–28)
ΔMMSE within 24 months	−4.64 ± 4.59 (− 13.33–2.88)
ApoE ε4 allele carrier status Homozygous/ heterozygous/ non-carrier	3 / 8 / 6

MCI Mild cognitive impairment, AD Alzheimer’s disease, SD Standard deviation, min Minimum, max Maximum, BL Baseline, CDR-SOB Clinical dementia rating scale-sum of boxes, Δ Changes between baseline and follow up adjusted to a 24 months follow up period, negative values indicate decrease, positive values indicate increase compared to BL, MMSE Mini-mental state examination, ApoE Apolipoprotein E

ISSN: 1471-2377